Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be required to treat patients with advanced disease or complex cases.

The DRD Cure Accelerator, highlighted at the CCOI-Stanford Summit, is a global initiative advancing clinical research and ...

A patient suffering from a genetic eye disorder in Italy regained his sight thanks to a world-first experimental gene therapy ...